Introduction {#S0001}
============

Anti-tumor necrosis factors (anti-TNFs) are biologic disease-modifying antirheumatic drugs (bDMARDs) effective in treating multiple chronic inflammatory diseases, including rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), and psoriatic arthritis (PsA).[@CIT0001],[@CIT0002] Anti-TNFs can be self-administered by subcutaneous injection. This method of administration can increase patient independence, improve patient satisfaction, and allow patients to gain better control of their treatment schedule.[@CIT0003]--[@CIT0005]

Although self-injection may improve patient treatment experience,[@CIT0005] there are several barriers to successful self-injection. Psychological and social barriers, such as injection anxiety, needle phobia, and lack of confidence, are reported among patients who self-inject.[@CIT0005] Physical barriers can also impede safe self-injection, such as hand dexterity problems and pain, which are commonly found in RA patients.[@CIT0005]--[@CIT0007] Together, these barriers can lead to poor treatment adherence and, consequently, poor clinical and economic outcomes.[@CIT0002],[@CIT0004]

A number of treatment delivery factors have been shown to impact patient medication adherence; optimizing device design to fulfill any unmet needs and meet patient expectations may enhance patient experience, improve disease management, and reduce treatment non-adherence.[@CIT0001] As a result, research into patient-reported preferences and outcomes has directed and advanced the development of self-injection devices.[@CIT0003] Evidence from focus groups suggests patient views on what constitutes an "ideal device" can vary, with patients valuing alternative features differently.[@CIT0008] Differences in preferences may be driven by a number of factors, for example, the impact of disease on joint mobility, patient lifestyle, chronic disease longevity and management, and fears and beliefs around disease.[@CIT0009],[@CIT0010] Discrete-choice experiments (DCE) are routinely used to elicit individuals' preferences and can be used when comparing health care technologies.[@CIT0011],[@CIT0012] For example, a DCE study examining the preferences of RA patients highlighted differences in administration route preferences, demonstrating that subcutaneous injection was preferred when considering convenience.[@CIT0013]

Reusable electromechanical self-injection devices (e-Devices) with a dose dispenser cartridge are now approved for delivery of anti-TNF treatments in Europe.[@CIT0014],[@CIT0015] Patient feedback from human factor studies was used in the development of e-Device designs to ensure the final design addressed patient needs more effectively than existing options.[@CIT0001] The e-Device incorporates a number of enhanced features including injection speed control to reduce patient anxiety and increase injection comfort, an injection log to track medication compliance, a "next injection" notification feature, a skin sensor to prevent injection misfire and drug wastage, step-by-step on-screen instructions and training cartridge to help increase patient confidence, and an ergonomic grip to enhance handling and control.[@CIT0014]

The primary objective of this study was to use a DCE to elicit patients' preferences for a set of enhanced features that differentiate e-Devices from other currently marketed pre-filled pens. Other objectives included calculating patients' willingness to pay (WTP) for enhanced features, to quantify patients' relative preference for different hypothetical device profiles and features. Additionally, this study aimed to explore whether disease condition, disease severity, and self-injection experience were associated with systematic differences in preferences.

Materials and methods {#S0002}
=====================

Patient eligibility and data collection {#S0002-S2001}
---------------------------------------

Physicians in the UK were contracted by the healthcare research company, AplusA (London, UK), to invite patients with RA, PsA, and axSpA to participate in the study. Physicians (both GPs and specialists) who had previously agreed to refer patients for surveys were contacted by email or by phone and email. All patients were aged ≥18 years, had a moderate or severe diagnosis of the conditions based on the physician's clinical judgment, were residents of the UK, and could read and understand English. Patients' physicians provided confirmation of disease condition and severity.

Once interest in study participation was received from the patient, a link to the study survey was sent via email. Initial questions were used to assess the patient's eligibility to participate. Eligible patients provided informed, electronic consent before being asked to complete the study survey. All patients were paid nominal remuneration to compensate them for their time to complete the study surveys. Patient demographic data including age, level of education, employment status, and household income were collected. Additionally, data about each patient's disease history were recorded, including time since diagnosis, disease severity and previous treatment and self-injection experience.

Discrete-choice experiment {#S0002-S2002}
--------------------------

Following recommended research practices,[@CIT0016] a DCE survey was developed to elicit preferences and WTP for a set of enhanced self-injection device features (skin sensor functionality, injection speed control, step-by-step on-screen instructions, injection date reminder, electronic log) and having a large, instead of a small grip, in patients with RA, axSpA, and PsA. To select these enhanced device features to be assessed in the DCE, the study team reviewed focus group reports from the study sponsor, as well as the available literature.[@CIT0017],[@CIT0018] The study team then selected the device features that appeared to be most important to patients during the focus groups and which differentiated devices that may be available in the near future. Each DCE choice question included three device profiles: a standard disposable device with no enhanced features and a small grip, and two hypothetical reusable device profiles (reusable device A and reusable device B), characterized by different combinations of enhanced features. To elicit patients' WTP, the DCE included a cost attribute as a one-off payment for the device. The out-of-pocket cost of the standard disposable device was set to £0.

Before administering the DCE survey, 14 qualitative face-to-face pretest interviews and 1 telephone interview were conducted with a convenience sample of patients with RA, axSpA, or PsA from the UK. The interviews were used to ensure the survey was usable and understandable, and tested the levels of the "out-of-pocket" cost attribute of the survey. To ensure the "out-of-pocket" costs were reasonable, patients in the initial five pretest interviews completed the DCE assuming cost was constant between all devices and were then asked to suggest the cost they would be willing to pay for each feature.

The cost levels included in the hypothetical reusable device profiles ranged from £15 to £250. A scope test (or partial internal validity test) was performed to further confirm the cost was presented and interpreted correctly in the online survey, ie, that respondents evaluated a given difference in cost similarly, regardless of whether the cost change occurred within a narrow range of costs or within a wide range of costs. To perform the scope test, respondents were randomly assigned to 1 of 2 different split samples with different ranges of out-of-pocket cost: i) narrow range (£0, £15, £30, £50, £90, and £150) and ii) wide range (£0, £15, £30, £50, £125, and £250).[@CIT0019]

Although patients were asked to consider the out-of-pocket cost for a new device, UK patients do not currently pay for their devices. Therefore, to clarify that the purpose of the survey was to elicit the value, and not the price of the features, a short budget reminder, sometimes also referred to as "cheap talk" script, was included in the survey before the DCE questions (Supplementary Materials).[@CIT0019] The combinations of enhanced hypothetical reusable device features and out-of-pocket costs were determined using an experimental design developed using a D-efficient algorithm.[@CIT0020] This allowed for the estimation of a preference weight for each attribute level included in the study.

The survey was programmed and hosted online by AplusA between November 15, 2017 and February 15, 2018. Based on the number of device attributes, as well as the number of cost levels included, a total of 40 DCE questions was considered the optimal number to have sufficient observations to estimate the models. The experimental design therefore comprised 40 DCE questions, divided into 4 different blocks. Each respondent was assigned to 1 of the 4 blocks, each of which featured just 10 questions, to avoid individual respondents becoming fatigued. Within each block, the DCE questions were also randomized to mitigate ordering effects. An example DCE question is presented in [Figure 1](#F0001){ref-type="fig"}.Figure 1Example DCE question. The final experimental design included 40 sets of 3 devices split into 4 blocks of 10 hypothetical choice questions. Patients were randomly assigned to 1 block of 10 questions. Questions were randomly ordered to avoid ordering effects.

Statistical analyses {#S0002-S2003}
--------------------

Descriptive analyses were conducted to summarize respondent demographics. Continuous variables were summarized using mean, standard deviation (SD), median, and range; categorical data were summarized using frequencies and percentages.

Responses to the DCE questions were analyzed using a random-parameters logit (RPL) error component model.[@CIT0021] "Out-of-pocket cost" was interacted with the natural log of the respondents' income to control for income effects and assumed to be a linear and a continuous function of the levels of "out-of-pocket cost" shown to respondents. Before DCE data modeling, a scope test on the out-of-pocket cost was performed on all collected data. This tested whether respondents paid attention to the absolute numeric values presented in the survey as out-of-pocket cost or interpreted the numeric levels presented qualitatively as high, medium, and low.[@CIT0019]

All other attributes were categorical, and effects-coded as 1 when the attribute level "yes" was included in the profile and −1 when the attribute level "no" was included. An RPL error component model was estimated to capture preference heterogeneity for a hypothetical reusable device over a standard disposable device.[@CIT0022] The estimates from the RPL model were log-odds associated with each attribute level and were interpreted as relative preference weights. Each preference weight indicated the relative strength of preference for the attribute level, and a higher preference weight corresponded to a more preferred level of an attribute.

### Subgroup analysis {#S0002-S2003-S3001}

Preference weights for the attributes included in the DCE were estimated for three prespecified subgroups of interest: condition (axSpA, PsA, RA); physician assessment of disease severity (severe, moderate); and self-injection experience (naïve, experienced). WTP was also calculated for each subgroup. Differences between subgroups by age and gender were also investigated.

Interaction models were estimated for each subgroup to estimate differences in mean preferences between subgroups. A dummy variable indicating a specific subgroup was interacted with each attribute level in the study. The unobserved heterogeneity captured by the RPL was assumed to be constant across subgroups. The explanatory variables in the interaction model included both the full set of attribute levels and the full set of interactions. A Wald test was used to determine the joint statistical significance of differences between each subgroup.[@CIT0023]

Analyses were conducted using NLOGIT 5.0 (Econometric Software, Plain View, NY, USA).

### Welfare analysis {#S0002-S2003-S3002}

The inclusion of the out-of-pocket cost in the DCE forced tradeoffs between the benefit gained from the inclusion of a specific feature in the device and the loss caused by having to pay for it. The preference weight for the out-of-pocket cost was interpreted as the incremental disutility caused by a one-off payment of one additional pound for the reusable device with a combination of enhanced features. The ratio between the utility gained when including the additional device feature and the disutility of cost (known as WTP) can be interpreted as the welfare gain a patient would obtain by including the additional feature in the device.

Since the experimental design included a reference self-injection device with a zero out-of-pocket cost and no enhanced features, it was possible to compute the value of specific combinations of enhanced features in a reusable self-injection device by the compensating variation (CV) (Supplementary Materials).[@CIT0024] The value associated with a reusable device with all the enhanced features and a large grip, compared to the standard disposable device with small grip was calculated.

Ethical considerations {#S0002-S2004}
----------------------

The RTI International Institutional Review Board (IRB) determined that this study meets the criteria for IRB exemption under the Code of Federal Regulations (section 45CFR46.101(b) specifically) because the research involved the use of survey procedures, the information obtained was recorded in such a manner that human subjects could not be identified, directly or through identifiers linked to the subjects, and any disclosure of the human subjects' responses outside the research would not reasonably place the subjects at risk of criminal or civil liability or be damaging to the subjects' financial standing, employability, or reputation. In the qualitative pretest interviews, each interview participant signed and dated an informed consent form before the interview. All respondents to the DCE survey provided electronic informed consent and received nominal compensation for time spent participating. The study complied with the Declaration of Helsinki.

Results {#S0003}
=======

Patient characteristics {#S0003-S2001}
-----------------------

Over 1,000 physicians were contacted and 37 agreed to recruit patients for the survey. Links to the online survey were sent via email to 415 patients, 323 (77.8%) were eligible, provided informed consent, and completed the survey. The mean (SD) patient age was 48.6 years (13.7) and 200 (61.9%) were female. Of the 323 patients, 151 (46.7%) had no previous self-injection experience ([Table 1](#T0001){ref-type="table"}). The demographics of patients stratified by condition are presented in [Table 2](#T0002){ref-type="table"}. Of the 323 patients, 112 (34.7%) were diagnosed with axSpA, 103 (31.9%) with PsA and 108 (33.4%) with RA. Within the disease subgroups, 53/103 (51.5%) PsA patients, 57/108 (52.8%) RA patients, and 51/112 (45.5%) axSpA patients were classified by their physician as having moderate disease severity. 53/103 (51.5%) PsA patients, 58/108 (53.7%) RA patients, and 61/112 (54.5%) axSpA patients had experience with self-injection ([Table 3](#T0003){ref-type="table"}).Table 1Patient demographics, all patients (N=323)All patients, n (%)Age, years, mean (SD)^a^48.6 (13.7)Gender Female200 (61.9) Male122 (37.8) Prefer not to say1 (0.3)Time since diagnosis \<2 years47 (14.6) 2--\<4 years63 (19.5) 4--\<10 years94 (29.1) ≥10 years117 (36.2) Unknown/unsure2 (0.6)Previous experience using a self-injection device Yes172 (53.3) No151 (46.7)Level of education No formal education1 (0.3) Primary school education or less6 (1.9) Secondary school education up to general/ordinary/standard level^b^72 (22.3) Secondary school education up to intermediate/advanced/higher level^c^46 (14.2) Professional or work-related qualifications^d^79 (24.5) Undergraduate university degree61 (18.9) Postgraduate university degree or equivalent45 (13.9) Preferred not to answer13 (4.0)Employment status Employed, full-time112 (34.7) Employed, part-time54 (16.7) Self-employed21 (6.5) Homemaker11 (3.4) Student11 (3.4) Retired56 (17.3) Disabled/unable to work33 (10.2) Unemployed but looking for work14 (4.3) Unemployed and not looking for work2 (0.6) Preferred not to answer9 (2.8)Household income^e^ Less than £25,00078 (24.1) £25,000 to £49,99990 (27.9) £50,000 to £74,99953 (16.4) £75,000 to £99,99924 (7.4) £100,000 to £149,9995 (1.5) £150,000 to £199,9991 (0.3) Unknown/unsure16 (5.0) Preferred not to answer56 (17.3)[^1][^2] Table 2Respondent demographics by condition subgroup (N=323)Respondents with axSpARespondents with PsARespondents with RAAll respondents**Age (years)** n112103107322 Mean (SD)48.4 (14.4)48.5 (12.4)49.0 (14.3)48.6 (13.7) Median48.548.050.048.0 Min, max20, 8321, 7919, 8919, 89 Missing0011**Country of residence, n (%)** N112103108323 England106 (94.6)99 (96.1)95 (88.0)300 (92.9) Scotland2 (1.8)4 (3.9)9 (8.3)15 (4.6) Wales4 (3.6)02 (1.9)6 (1.9) Northern Ireland002 (1.9)2 (0.6) Other -- EU country0000 Other -- non-EU country0000**Condition diagnosis,^a^ n (%)** n112103108323 Allergies12 (10.7)10 (9.7)8 (7.4)30 (9.3) axSpA112 (100)00112 (34.7) Anxiety16 (14.3)12 (11.7)12 (11.1)40 (12.4) Obesity9 (8.0)9 (8.7)6 (5.6)24 (7.4) Osteoarthritis10 (8.9)10 (9.7)16 (14.8)36 (11.1) COPD02 (1.9)1 (0.9)3 (0.9) Diabetes7 (6.3)3 (2.9)9 (8.3)19 (5.9) Depression22 (19.6)16 (15.5)18 (16.7)56 (17.3) Fibromyalgia7 (6.3)9 (8.7)9 (8.3)25 (7.7) High blood pressure/hypertension25 (22.3)15 (14.6)13 (12.0)53 (16.4) High cholesterol15 (13.4)11 (10.7)13 (12.0)39 (12.1) Insomnia3 (2.7)6 (5.8)3 (2.8)12 (3.7) PsA7 (6.3)103 (100)0110 (34.1) RA6 (5.4)8 (7.8)108 (100)122 (37.8) None of the above0000**Gender, n (%)** n112103108323 Female50 (44.6)64 (62.1)86 (79.6)200 (61.9) Male62 (55.4)38 (36.9)22 (20.4)122 (37.8) Other0000 Prefer not to answer01 (1.0)01 (0.3)**Marital status, n (%)** n112103108323 Single/never married34 (30.4)17 (16.5)21 (19.4)72 (22.3) Married/living as married/civil partnership56 (50.0)70 (68.0)73 (67.6)199 (61.6) Divorced or separated15 (13.4)13 (12.6)10 (9.3)38 (11.8) Widowed/surviving partner2 (1.8)3 (2.9)3 (2.8)8 (2.5) Other3 (2.7)003 (0.9) Prefer not to answer2 (1.8)01 (0.9)3 (0.9)**Highest level of education, n (%)** n112103108323 No formal education01 (1.0)01 (0.3) Primary school education or less1 (0.9)3 (2.9)2 (1.9)6 (1.9) Secondary school education up to general, ordinary, or standard level25 (22.3)27 (26.2)20 (18.5)72 (22.3) Secondary school education up to intermediate, advanced, or higher level14 (12.5)18 (17.5)14 (13.0)46 (14.2) Professional or work-related qualifications obtained from a college or university26 (23.2)23 (22.3)30 (27.8)79 (24.5) Undergraduate university degree22 (19.6)12 (11.7)27 (25.0)61 (18.9) Postgraduate university degree or equivalent qualification20 (17.9)11 (10.7)14 (13.0)45 (13.9) Prefer not to answer4 (3.6)8 (7.8)1 (0.9)13 (4.0)**Employment status, n (%)** n112103108323 Employed full-time44 (39.3)33 (32.0)35 (32.4)112 (34.7) Employed part-time15 (13.4)23 (22.3)16 (14.8)54 (16.7) Self-employed7 (6.3)7 (6.8)7 (6.5)21 (6.5) Homemaker3 (2.7)5 (4.9)3 (2.8)11 (3.4) Student5 (4.5)2 (1.9)4 (3.7)11 (3.4) Retired21 (18.8)15 (14.6)20 (18.5)56 (17.3) Disabled/unable to work9 (8.0)10 (9.7)14 (13.0)33 (10.2) Unemployed but looking for work5 (4.5)5 (4.9)4 (3.7)14 (4.3) Unemployed and not looking for work002 (1.9)2 (0.6) Prefer not to answer3 (2.7)3 (2.9)3 (2.8)9 (2.8)**Household income before tax and other deductions in 2016, n (%)** n112103108323 Less than £25,00030 (26.8)26 (25.2)22 (20.4)78 (24.1) £25,000 to £49,99929 (25.9)30 (29.1)31 (28.7)90 (27.9) £50,000 to £74,99917 (15.2)14 (13.6)22 (20.4)53 (16.4) £75,000 to £99,9997 (6.3)10 (9.7)7 (6.5)24 (7.4) £100,000 to £149,9993 (2.7)1 (1.0)1 (0.9)5 (1.5) £150,000 to £199,9991 (0.9)001 (0.3) £200,000 or more0000 Don't know/not sure6 (5.4)4 (3.9)6 (5.6)16 (5.0) Prefer not to answer19 (17.0)18 (17.5)19 (17.6)56 (17.3)[^3][^4] Table 3Patients stratified by disease indicationaxSpA n=112PsA n=103RA n=108**Physician-assessed disease severity, n (%)** Moderate51 (45.5)53 (51.5)57 (52.8) Severe61 (54.5)50 (48.5)51 (47.2)**Self-injection experience, n (%)** Self-injection experienced61 (54.5)53 (51.5)58 (53.7) Self-injection naïve51 (45.5)50 (48.5)50 (46.3)[^5]

DCE preference analysis {#S0003-S2002}
-----------------------

The scope test, conducted by assigning half of the respondents to a narrow range (£0, £15, £30, £50, £90, and £150) and half to a wide range (£0, £15, £30, £50, £125, and £250) of out-of-pocket costs, suggested respondents paid attention to the absolute numeric values, rather than interpreting the numeric levels as qualitative categories such as low, medium, and high. Therefore, the data from both cost ranges were pooled for the remaining analyses.

[Table 4](#T0004){ref-type="table"} presents results from the RPL model estimation. On average, respondents preferred self-injection devices with enhanced features over a standard self-injection. However, respondents did not show a statistically significant preference for a large or small grip size. The order of importance for each attribute can be extrapolated from the preference estimated parameters as all attributes could assume only two values (yes/no or large/small). The skin sensor was the most important, with the highest preference weight for inclusion in the device, followed by electronic log, injection speed control and injection date reminder, step-by-step on-screen instructions, and grip size.Table 4Random parameters logit estimates (N=323)AttributePreference weight95% confidence intervalSkin sensor0.725\*\*0.5520.897Control of the speed of injection0.455\*\*0.3200.591Step-by-step, on-screen instructions in real time0.304\*\*0.1820.427Injection date reminder0.438\*\*0.2920.584Electronic log0.497\*\*0.3690.626Large grip size−0.181−0.4240.062Out-of-pocket cost£04.297\*\*3.4725.122£153.571\*\*2.8854.256£302.844\*\*2.2983.391£501.876\*\*1.5162.236£90−0.061\*\*−0.072−0.049£125−1.755\*\*−2.092−1.418£150−2.965\*\*−3.535−2.396£250−7.807\*\*−9.306−6.308Constant for standard disposable self-injection device0.338−0.2860.961[^6]

### Subgroup analysis {#S0003-S2002-S3001}

When comparing a reusable self-injection device without any enhanced features and the standard disposable self-injection device, axSpA respondents had a statistically significant preference for a disposable standard self-injection device, while RA and PsA did not have a strong preference between the standard disposable device and a reusable device ([Table 5](#T0005){ref-type="table"}). Patients with physician-assessed severe condition (across all indications) significantly preferred a disposable standard self-injection device, while respondents with physician-assessed moderate condition significantly preferred a reusable device ([Table 6](#T0006){ref-type="table"}). Patients with self-injection experience were significantly more likely to select the disposable standard self-injection device, while self-injection naïve respondents had no preference ([Table 7](#T0007){ref-type="table"}).Table 5Random parameters logit regression results: condition subgroups (N=323)AttributePreference weight95% confidence interval**axSpA Subgroup**Skin sensor0.988\*\*0.6781.297Control of the speed of injection0.659\*\*0.4280.891Step-by-step, on-screen instructions in real time0.235\*0.0110.459Injection date reminder0.733\*\*0.4651.000Electronic log0.655\*\*0.4170.892Large grip size−0.731\*\*−1.136−0.325Out-of-pocket cost£04.855\*\*3.8495.862£154.035\*\*3.1984.871£303.214\*\*2.5483.881£502.120\*\*1.6802.560£90−0.068\*\*−0.083−0.054£125−1.983\*\*−2.394−1.572£150−3.351\*\*−4.046−2.656£250−8.822\*\*−10.651−6.993Constant for standard disposable self-injection device1.681\*\*0.6242.739**PsA Subgroup**Skin sensor0.773\*\*0.4511.096Control of the speed of injection0.442\*\*0.2160.668Step-by-step, on-screen instructions in real time0.402\*\*0.1690.635Injection date reminder0.444\*\*0.2060.681Electronic log0.476\*\*0.2570.694Large grip size0.516\*\*0.1280.904Out-of-pocket cost£04.892\*\*3.6176.166£154.065\*\*3.0065.124£303.238\*\*2.3954.082£502.136\*\*1.5792.692£90−0.069\*\*−0.087−0.051£125−1.998\*\*−2.518−1.477£150−3.376\*\*−4.255−2.496£250−8.888\*\*−11.203−6.572Constant for standard disposable self-injection device0.457−0.5641.478**RA Subgroup**Skin sensor0.589\*\*0.3030.875Control of the speed of injection0.577\*\*0.3420.812Step-by-step, on-screen instructions in real time0.280\*\*0.0690.491Injection date reminder0.480\*\*0.2370.723Electronic log0.433\*\*0.2040.662Large grip size0.193−0.2350.622Out-of-pocket cost£03.708\*\*2.9054.512£153.082\*\*2.4143.750£302.455\*\*1.9232.987£501.619\*\*1.2681.970£90−0.052\*\*−0.064−0.041£125−1.515\*\*−1.843−1.186£150−2.559\*\*−3.114−2.005£250−6.738\*\*−8.198−5.277Constant for standard disposable self-injection device−0.933−2.7570.891[^7] Table 6Random parameters logit regression results: disease severity subgroups (N=323)AttributePreference weight95% confidence interval**Severe disease subgroup**Skin sensor0.953\*\*0.6971.210Control of the speed of injection0.529\*\*0.3240.734Step-by-step, on-screen instructions in real time0.331\*\*0.1220.540Injection date reminder0.474\*\*0.2650.684Electronic log0.512\*\*0.3110.714Large grip size0.145−0.2200.510Out-of-pocket cost£05.098\*\*4.1886.008£154.236\*\*3.4804.992£303.375\*\*2.7733.977£502.226\*\*1.8292.623£90−0.072\*\*−0.085−0.059£125−2.082\*\*−2.454−1.711£150−3.518\*\*−4.146−2.891£250−9.263\*\*−10.916−7.610Constant for standard disposable self-injection device1.474\*\*0.4662.481**Moderate disease subgroup**Skin sensor0.566\*\*0.3410.790Control of the speed of injection0.422\*\*0.2490.594Step-by-step, on-screen instructions in real time0.299\*\*0.1260.472Injection date reminder0.610\*\*0.4110.810Electronic log0.491\*\*0.3130.669Large grip size−0.458\*\*−0.787−0.128Out-of-pocket cost£04.286\*\*3.4885.084£153.562\*\*2.8994.225£302.837\*\*2.3093.366£501.871\*\*1.5232.220£90−0.060\*\*−0.072−0.049£125−1.751\*\*−2.077−1.425£150−2.958\*\*−3.509−2.407£250−7.788\*\*−9.238−6.338Constant for standard disposable self-injection device−0.821\*−1.574−0.067[^8] Table 7Random parameters logit regression results: self-injection experience subgroups (N=323)AttributePreference weight95% confidence intervalNo self-injection experience subgroupSkin sensor0.755\*\*0.5350.975Control of the speed of injection0.555\*\*0.3610.749Step-by-step, on-screen instructions in real time0.372\*\*0.2040.540Injection date reminder0.446\*\*0.2540.638Electronic log0.529\*\*0.3460.712Large grip size−0.153−0.4740.169Out-of-pocket cost£03.758\*\*3.0244.492£153.123\*\*2.5133.733£302.488\*\*2.0022.973£501.641\*\*1.3201.961£90−0.053\*\*−0.063−0.043£125−1.535\*\*−1.835−1.235£150−2.594\*\*−3.100−2.087£250−6.828\*\*−8.161−5.494Constant for standard disposable self-injection device−0.486−1.3600.389**Self-injection experience subgroup**Skin sensor0.679\*\*0.3820.976Control of the speed of injection0.470\*\*0.2220.717Step-by-step, on-screen instructions in real time0.278\*\*0.0720.484Injection date reminder0.778\*\*0.5261.029Electronic log0.461\*\*0.2370.685Large grip size−0.536\*\*−0.871−0.201Out-of-pocket cost£06.007\*\*4.7577.257£154.992\*\*3.9536.031£303.977\*\*3.1494.804£502.623\*\*2.0773.169£90−0.085\*\*−0.102−0.067£125−2.454\*\*−2.964−1.943£150−4.146\*\*−5.009−3.283£250−10.914\*\*−13.186−8.643Constant for standard disposable self-injection device1.882\*\*0.6153.148[^9]

On average, respondents in each subgroup significantly preferred self-injection devices enhanced with any of the features included in the DCE, excluding grip size, which varied across subgroups. Specifically, respondents with axSpA significantly preferred a small grip, while PsA significantly preferred a large grip ([Table 5](#T0005){ref-type="table"}). Respondents with moderate condition (across all conditions) significantly preferred a small grip, while respondents with severe condition qualitatively preferred a large grip; however, preference weights were not statistically significant ([Table 6](#T0006){ref-type="table"}).

Further post-hoc subgroup analyses were carried out using a Wald test for systematic differences in preferences to investigate if age or gender influenced patient preference and if there were any significant differences compared to the overall population; however, no differences were found.

### Welfare analysis {#S0003-S2002-S3002}

Despite residing in a health care system where the majority of treatment is free at the point of use, patients were willing to pay for an enhanced device. Patients were willing to pay for each different additional feature, with most to least valued being skin sensor (£30), injection speed control, injection reminders, electronic log (\~£20 each), on-screen instructions (\~£12), and grip size (\~£7) ([Figure 2](#F0002){ref-type="fig"}). Similar results were observed when patients were analyzed by subgroup with patients willing to pay for any of the enhanced features, except for grip size ([Figure 3A](#F0003){ref-type="fig"}--[C](#F0003){ref-type="fig"}).Figure 2Total population willingness to pay for each enhanced feature (N=323).Figure 3Population subgroup willingness to pay for each enhanced feature. (**A**) Willingness to pay for each enhanced feature by condition; (**B**) Willingness to pay for each enhanced feature by disease severity; (**C**) Willingness to pay to each enhanced feature by self-injection experience.

When all enhanced features were considered together in a single hypothetical device (ie, calculating CV \[Supplementary Materials\]), all patients and all subgroups of patients valued the device over a standard disposable device ([Figure 4](#F0004){ref-type="fig"}). On average, respondents were willing to pay £85 for a reusable device with all enhanced features. However, there were variations in the amount patients were willing to pay for an enhanced device. Self-injection naïve and RA respondents were willing to pay the most (\~£130 and \~£145, respectively), whereas patients with self-injection experience were only willing to pay £35 for the same hypothetical device.Figure 4Sample and subgroup valuation of an enhanced, reusable self-injection device with all enhanced features and large grip compared to a standard disposable device (N=323). A standard disposable self-injection device has no features, small grip, and no out-of-pocket cost associated with it.

Discussion {#S0004}
==========

Self-injection can offer convenience and independence for patients; however, factors associated with self-injection and treatment delivery can affect patient adherence to medication.[@CIT0003],[@CIT0004] Differences in patient subgroup preferences for certain device features have previously been reported.[@CIT0015],[@CIT0025] These results suggest that optimizing device design to meet patient needs, expectations and preferences may help to improve patient experience.[@CIT0001] The results of this study demonstrate that despite certain subgroups preferring a standard disposable device over a reusable device without enhanced features, all patients preferred a self-injection device with enhanced features over a device with no enhanced features. It is important to note that respondents were willing to pay for an enhanced device despite living in the UK, which has a health care system where patients typically do not pay or pay very little at the point of delivery for prescribed medication or medical devices. Carrying out the same DCE in a country in which residents pay more for their health care at the point of delivery may find respondents are willing to pay more for the same enhanced device.

Generally, all disease subgroups valued the skin sensor more than other enhanced features, while the on-screen instructions were not as highly valued by all disease subgroups. Differences in patient preference for grip size were observed; axSpA patients preferred a small grip size, PsA patients preferred a large grip size, and RA patients did not express a significant preference. The different preferences for grip size among patients may be caused by the impact the disease has on hand dexterity. axSpA is a condition that primarily affects the axial skeleton, whereas PsA and RA generally affect smaller joints, such as the finger, thumb, and wrist joints in the hands.[@CIT0026]--[@CIT0028] The large grip was designed for patients who struggle with self-injection as they have trouble holding objects, so patients whose condition affects hand dexterity may express a preference for the large grip. RA patients did not show a statistically significant preference for the large grip despite often having hand dexterity problems. However, this may be due to RA patients with different levels of disease severity preferring different grip sizes. It may be that severe RA patients show a preference for a large grip, but RA patients with moderate disease do not.

In addition to differences in patient subgroup preferences for individual features, these results revealed differences in the willingness of patients to pay for a new device. Specifically, self-injection naïve patients were willing to pay more than self-injection experienced patients for a device with the same enhanced features. Previous studies have shown that self-injection naïve patients have more self-injection anxieties and need more support.[@CIT0018],[@CIT0029] Therefore, the higher WTP among naïve patients may be driven by the extra support (eg, step-by-step on-screen instructions) and certainty (eg, as given by the skin sensor) the enhanced device provides. In contrast, experienced patients are more familiar with self-injection and may have a routine, needing less assistance from a device to feel comfortable with the self-injection process.[@CIT0018] This is supported by the results showing that self-injection experienced patients and patients with moderate disease control are willing to pay less for every enhanced feature, compared to self-injection naïve patients.

The differences in patient preferences observed in our study support a targeted approach to device design and demonstrate that a choice of injection devices is important for patient satisfaction. A previous DCE study found that, while there is heterogeneity in RA patient treatment preference, patients generally fall into one of the five "preference" groups. Each preference group had a different top priority when deciding which treatment to use including avoiding side effects that impact quality of life, receiving fast-acting medicine, avoiding needles, avoiding life-threatening adverse events and treatment affordability. Determining which group a patient falls into could aid decisions about which self-injection device may best suit their priorities and help remove barriers to self-injection.[@CIT0030] Providing a portfolio of different self-injection devices could help meet the needs of multiple different "preference" groups and allow patients to choose a device that best fits their individual needs. For example, a patient with hand dexterity problems may prefer to use a device with a larger grip, while a patient without disease affecting their hands may prefer a device with a smaller grip.

Several previous studies have validated the use of DCE and WTP methodology in a rheumatology population.[@CIT0012],[@CIT0031],[@CIT0032] Both methods have been found to be reliable over time, and WTP has been shown to consistently assess symptom severity over time, suggesting the method has good construct validity.[@CIT0012],[@CIT0031] Overall, these studies support the use of the DCE and WTP methods to investigate patient preference.

Limitations {#S0004-S2001}
-----------

This study was associated with several limitations. There was the potential for self-selection bias as patients could decide whether to participate in the survey. Additionally, patients were recruited via a small number of physicians possibly introducing further selection bias as physicians could also choose to participate in the study. The attributes of the treatment alternatives presented in the survey mimicked those of real-world devices as closely as possible; however, they were hypothetical devices and so the results were subject to potential hypothetical bias. Patients were not able to handle the devices, so it may be more difficult for respondents to evaluate features such as grip size. Not all attributes of a device were included in the survey, and the results from this study related only to attributes and attribute levels defined in the survey. Attributes were chosen based on the opinions of health care professionals (HCPs) at an advisory board and on patient preferences in previous studies.[@CIT0017],[@CIT0018] It is possible that this could have introduced bias to the attributes included, as choice was partly patient-driven and partly driven by the opinions of HCPs. In the UK, patients do not usually pay for medical devices which limits the generalizability of the results. For example, if the study was conducted in the US, where patients pay for their health care, patients might be willing to pay more for additional features. Despite this limitation, a positive WTP for different enhanced features, above what respondents stated they have paid for medical devices in the past, was found. Finally, it should be noted that treatment non-adherence has a variety of causes (not just treatment delivery factors)[@CIT0001] and that interventions to improve adherence have previously been shown to have modest effectiveness.[@CIT0033] Additional evidence may therefore be required to confirm the real-world impact of a reusable self-injection device with enhanced features on patient treatment adherence.

Conclusion {#S0005}
==========

Patients positively valued and were therefore willing to pay for reusable self-injection devices with enhanced features, compared to a disposable self-injection device with no enhanced features. This suggests that patient experience may be improved by a self-injection device with these enhanced features and that current self-injection devices may not meet all needs of patients with RA, PsA, and axSpA. A greater choice of injection devices, which could include enhanced features, may improve patient experience, satisfaction and treatment adherence and, therefore, treatment outcomes.
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Supplementary materials {#S0007}
=======================

Discrete choice experiment {#S0007-S2001}
--------------------------

### Budget reminder, also referred to as "cheap talk" script {#S0007-S2001-S3001}

To ensure patients understood that the purpose of the survey was to elicit the value, and not the price of the device features presented, the following "cheap talk" script was included in the survey before the DCE questions.

Before you answer the following questions, we want to ask you to help us with a problem we have in studies like this one. Because people do not really have to pay the cost of the device they would choose, they often do not focus on the actual amounts shown, but only whether one cost is larger than another cost.

For example, if the costs of the devices in the questions are £25, £50, and £100, people often think of them as just "low," "medium," and "high." They do not really think about what they would have to give up---such as a restaurant meal or some new clothes---if they had to pay (£25, £50, or £100) for the device.

This study will not be used to set prices for self-injection devices, but it will help decision makers understand how important device features are to people. If people do not pay attention to the amounts shown, our analysis will be wrong. We won't get a true measure of the value of self-injection device features to you.

Please help us measure your preferences correctly by carefully considering to the amounts shown before deciding which self-injection device you would choose.

Feature Descriptors {#S0007-S2002}
-------------------

### Description of Self-Injection Devices in the Survey {#S0007-S2002-S3001}

All self-injection devices are devices that allow you to inject yourself with medicine at home without having to go to a doctor's office or clinic. When you are ready to begin the injection, you place the end of the device firmly against your skin and start the injection, which can last up to 15 seconds. The needle is hidden in the device, and it is not visible before, during, or after the injection.

Standard devices are disposable pens that are prefilled with medicine and are often stored in the refrigerator. Once the injection is over, you throw away the whole device in a sharps bin.

The hypothetical devices with additional features come with disposable cartridges that are filled with medicine and are often stored in the refrigerator. Once the injection is over, you throw away the cartridge in a sharps bin, but the whole device is reusable for up to 3 years.

Before you can get a device with additional features, your doctor or pharmacist will need to set it up and customize it to your personal needs.

### Skin sensor {#S0007-S2002-S3002}

Some self-injection devices may have a skin sensor. This feature can detect whether the device is placed on your skin correctly and will not allow the injection to start until the device is in the proper place. If, for any reason, the device loses contact with the skin in the middle of an injection, the sensor will trigger an emergency stop to avoid losing any medicine.

### Control of the speed of the injection {#S0007-S2002-S3003}

Some self-injection devices may have a speed adjustment feature that allows you to control the speed of the injection.

If a device has this feature, you would be able to increase or decrease the speed at which the medicine is injected into your body. This allows you to inject the medicine at a speed that is most comfortable for you.

In addition, if the device has this feature, you would also be able to pause the injection by pressing a button on the injection device.

### Step-by-step on-screen instructions {#S0007-S2002-S3004}

Some self-injection devices may have a screen that presents step-by-step instructions while you use the device instead of listing the instructions in a separate booklet or leaflet. These on-screen instructions guide you through every step of the injection, from beginning to end. This feature will guide you throughout the injection process and give you warnings to help you know what to do in case you have a problem with the injection. The feature will also let you know when the injection has been completed.

### Injection date reminders {#S0007-S2002-S3005}

Some self-injection devices may use information about the time of your last injection to remind you when it is time for your next injection. The reminder will be sent to you by e-mail or text message shortly before you need to take your next injection. This information could also be delivered as an automatic message through an app or through the calendar feature on your smartphone or tablet.

### Electronic log {#S0007-S2002-S3006}

Some self-injection devices keep a log of the dose and date of each injection so that you and your doctor can monitor your treatment, knowing whether and when you took your medication. This information can be transmitted securely through a wireless connection (using a cellular or Wi-Fi network) to a computer, tablet, or smartphone, where you can access and analyze it using a computer program or app. The program or app will also allow you to enter information about your symptoms so that you and your doctor can monitor your health and the severity of your symptoms. If you would like, the program or app will also allow you to share this information with your doctor automatically.

### Grip size {#S0007-S2002-S3007}

Self-injection devices come in different sizes. Some have grips (the place where you hold the device in your hand) that are designed to make it easier to hold and to inject the medicine. [Figure S1](#SF0001) may help you think about the size of different injection devices. Figure S1Example DCE question. The final experimental design included 40 sets of 3 devices split into 4 blocks of 10 hypothetical choice questions. Patients were randomly assigned to 1 block of 10 questions. Questions were randomly ordered to avoid ordering effects.

Compensating Variation {#S0007-S2003}
----------------------

The Compensating Variation (CV) for a given reusable self-injection device compared with the current standard self-injection device with no enhanced features, small grip and no out-of-pocket cost, is defined by the following: $$\documentclass[12pt]{minimal}
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[^1]: **Notes:** ^a^n=322, age unknown for 1 patient; ^b^CSEs, GCSEs, O-levels, Scottish Standard Grades, or equivalent; ^c^A/S levels, A-levels, Scottish Intermediates, Scottish Highers, International/Scottish Baccalaureate or equivalent; ^d^Certificate of Higher Education, Diploma of Higher Education, foundation degree; ^e^Household income (2016) before tax and other deductions.

[^2]: **Abbreviation:** SD, standard deviation.

[^3]: **Notes:** ^a^Respondents had the option to select more than one response category. For this reason, the percentages may sum to more than 100%. Secondary school education up to general, ordinary, or standard level: CSEs, GCSEs, O-levels, Scottish Standard Grades, or equivalent. Secondary school education up to intermediate, advanced, or higher level: A/S levels, A-levels, Scottish Intermediates, Scottish Highers, International/Scottish Baccalaureate or equivalent; Professional or work-related qualifications obtained from a college or university: Certificate of Higher Education, Diploma of Higher Education, foundation degree or equivalent; Undergraduate university degree: BSc, BA or equivalent; Postgraduate university degree or equivalent qualification: PGCE, MSc, MA, MPhil, PhD, or equivalent.

[^4]: **Abbreviations:** axSpA, axial spondyloarthritis; COPD, chronic obstructive pulmonary disorder; EU, European Union; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SD, standard deviation.

[^5]: **Abbreviations:** axSpA, axial spondyloarthritis; PsA, psoriatic arthritis; RA, rheumatoid arthritis.

[^6]: **Notes:** All variables, with the exception of out-of-pocket cost, were dichotomous and effects-coded. We present coefficients estimates for the included features, the coefficient for excluded features is computed as the negative of it. Cost was included in the model as the interaction of continuous cost and the natural log of income. The preference weights were created using the estimated coefficient for cost. The parameters were modeled with normally distributed random parameters. An error component was included to better accommodate the opt-out bias that could be caused by the standard device alternative. \*\**P*≤0.01.

[^7]: **Notes:** All variables, with the exception of out-of-pocket cost, were dichotomous and effects-coded. Cost was included in the model as the interaction of continuous cost and the natural log of income. The preference weights in the table above have been created using the estimated coefficient for cost. Dummy-coded variables for PsA and RA were interacted with the main variables to model the subgroups. The parameters were modeled with normally distributed random parameters, assumed to be the same across the axSpA, PsA, and RA subgroups. Additionally, we included an error component to better accommodate the opt-out bias that could be caused by the standard device alternative. \*\**P*≤0.01; \* *P*≤0.05.

    **Abbreviations:** axSpA, axial spondyloarthritis; PsA, psoriatic arthritis; RA, rheumatoid arthritis.

[^8]: **Notes:** All variables, with the exception of out-of-pocket cost, were dichotomous and effects-coded. Cost was included in the model as the interaction of continuous cost and the natural log of income. The preference weights in the table above have been created using the estimated coefficient for cost. A dummy-coded variable for moderate disease was interacted with the main variables to model the subgroups. The parameters were modeled with normally distributed random parameters, assumed to be the same across the disease severity subgroups. Additionally, we included an error component to better accommodate the opt-out bias that could be caused by the standard device alternative. \*\**P*≤0.01; \* *P*≤0.05.

[^9]: **Notes:** All variables, with the exception of out-of-pocket cost, were dichotomous and effects-coded. Cost was included in the model as the interaction of continuous cost and the natural log of income. The preference weights in the table above have been created using the estimated coefficient for cost. A dummy-coded variable for self-injection experience was interacted with the main variables to model the subgroups. The parameters were modeled with normally distributed random parameters, assumed to be the same across the self-injection experience subgroups. Additionally, we included an error component to better accommodate the opt-out bias that could be caused by the standard device alternative. \*\**P*≤0.01.
